Windward Bio Group AG (WWB)
NASDAQ: WWBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
WWB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.45B
- EPS (TTM)
- -$1.18
- Dividend yield
- None
- 52-week range
- 18.35 – 33.99
- Day range
- 22.47 – 26.20
- Volume / Avg
- 158.59K / 434.33K
- Beta
- —
- Shares outstanding
- 59.58M
52-week range
WWB stock today
On Nov 20, WWB ended the session at $24.29, adding $0.275 (1.15%), versus the S&P 500's 3.70% decline. Trading was light, with 158.59K shares changing hands, about 37% of the average daily volume. At this level, WWB sits in the middle of its 52-week range of $18.35 to $33.99: 28.6% below the high, set on Nov 13, 2026 and 32.3% above the low.
Windward Bio Group has posted a net loss over the last twelve months (EPS of -$1.18), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Windward Bio Group
Company profileWindward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Luca Santarelli M.D.
- Headquarters
- Basel
- Employees
- 33
- IPO year
- 2026
- Website
- windwardbio.com
WWB news
All WWB news- Windward Bio to Participate at the Jefferies London Global Healthcare ConferenceGlobeNewswire
- Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Windward Bio Lists on Nasdaq, Shares Up 68% on DebutPR Newswire
- Innovative Immunology Biotech Windward Bio Lists on NasdaqPR Newswire
- Innovative Immunology Biotech Windward Bio Lists on NasdaqPR Newswire
Windward Bio Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs WWB |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs WWB |
| IMCRImmunocore Holdings plc ADR | 26.41 | -0.83% | $1.36B | vs WWB |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs WWB |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs WWB |
| NVAXNovavax Inc. | 7.47 | -3.24% | $1.23B | vs WWB |
| TSHATaysha Gene Therapies Inc. | 3.72 | -1.33% | $1.21B | vs WWB |
| VORVor Biopharma Inc. | 19.19 | +3.62% | $1.18B | vs WWB |
Indexes, lists and sector
Windward Bio Group stock FAQ
What is Windward Bio Group's stock price today?
WWB last traded at $24.29 as of Nov 20, 4:00 PM EST, up 1.15% on the day. Prices are delayed at least 15 minutes.
Who is Windward Bio Group's CEO?
Dr. Luca Santarelli M.D. is the chief executive officer of Windward Bio Group AG, which has about 33 employees.
What is the WWB 52-week high?
The 52-week high for WWB is $33.99 and the 52-week low is $18.35. The stock is currently 28.6% below its high.